FDA Approves GSK's Blenrep for Multiple Myeloma Treatment, Marking a Market Return on October 24, 2025 Approved Blenrep bortezomib dexamethasone Multiple Myeloma SmithKline Beecham United States Food and Drug Administration +
FDA Delays Blenrep Decision, Challenging GSK's Multiple Myeloma Comeback Plans on July 24, 2025 Blenrep Deferred Multiple Myeloma Neoplasms Ocular Toxicity PDUFA regulatory hurdles SmithKline Beecham United States Food and Drug Administration +
FDA Advisory Panel Rejects GSK's Blenrep in New Combinations Over Safety, Efficacy Concerns on July 18, 2025 Advisory Panel Blenrep concerns DREAMM Drug Approval Multiple Myeloma Ocular Toxicity Refractory Plasma Cell Myeloma Relapsing course Safety SmithKline Beecham trials United States Food and Drug Administration +
FDA Flags Eye Safety Concerns as GSK Seeks Blenrep's US Return on July 15, 2025 Advisory Committees Blenrep Drug Approval Eye Eye safety Multiple Myeloma relapsed/refractory multiple myeloma SmithKline Beecham Toxicity aspects United States United States Food and Drug Administration +
UK approval brings GSK's Blenrep back from the brink on April 18, 2025 Antibody-Drug Conjugates Approved Blenrep Cessation of life dexamethasone DREAMM-8 Multiple Myeloma Risk UK +